{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:32:24Z","timestamp":1789590744356,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1124\/dmd.120.000076","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T03:59:47Z","timestamp":1595995187000},"page":"841-848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Detection of Weak Organic Anion\u2013Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans"],"prefix":"10.1016","volume":"48","author":[{"given":"Yueping","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay K.","family":"Holenarsipur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Kandoussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Thanga","family":"Mariappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.120.000076_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/jpet.118.253062","article-title":"Comprehensive evaluation of the utility of 20 endogenous molecules as biomarkers of OATP1B inhibition compared with rosuvastatin and coproporphyrin I","volume":"368","author":"Barnett","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.120.000076_bib2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/cpt.983","article-title":"Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B-mediated drug-drug interactions using population pharmacokinetic modeling and simulation","volume":"104","author":"Barnett","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.000076_bib3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3109\/00498254.2015.1085111","article-title":"Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III","volume":"46","author":"Bednarczyk","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.120.000076_bib4","first-page":"498757","article-title":"Urinary elimination of coproporphyrins is dependent on ABCC2 polymorphisms and represents a potential biomarker of MRP2 activity in humans","volume":"2011","author":"Benz-de Bretagne","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1124\/dmd.120.000076_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/bcp.12326","article-title":"Urinary coproporphyrin I\/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance","volume":"78","author":"Benz-de Bretagne","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.120.000076_bib6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1592\/phco.28.7.883","article-title":"Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis","volume":"28","author":"Beringer","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.120.000076_bib7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/cpt.1216","article-title":"Clinical probes and endogenous biomarkers as substrates for transporter drug-drug interaction evaluation: perspectives from the international transporter consortium","volume":"104","author":"Chu","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.000076_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00003088-198106020-00004","article-title":"Clinical pharmacokinetics of probenecid","volume":"6","author":"Cunningham","year":"1981","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.120.000076_bib9","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1002\/jps.24489","article-title":"The use of transporter probe drug cocktails for the assessment of transporter-based drug-drug interactions in a clinical setting-proposal of a four component transporter cocktail","volume":"104","author":"Ebner","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.120.000076_bib10","first-page":"3846","article-title":"Interaction of probenecid with methotrexate transport and release in the isolated rat hepatocyte in suspension","volume":"44","author":"Gewirtz","year":"1984","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.120.000076_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.120.000076_bib12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1124\/dmd.116.074740","article-title":"Coproporphyrin-I: a fluorescent, endogenous optimal probe substrate for ABCC2 (MRP2) suitable for vesicle-based MRP2 inhibition assay","volume":"45","author":"Gilibili","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000076_bib13","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1124\/dmd.109.031518","article-title":"Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters","volume":"38","author":"Han","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000076_bib14","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/dmd.106.009290","article-title":"Drug-drug interaction between pitavastatin and various drugs via OATP1B1","volume":"34","author":"Hirano","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000076_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/j.1552-4604.1990.tb03438.x","article-title":"The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers","volume":"30","author":"Inotsume","year":"1990","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.120.000076_bib16","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1046\/j.1523-1755.2000.00251.x","article-title":"Cellular and molecular aspects of drug transport in the kidney","volume":"58","author":"Inui","year":"2000","journal-title":"Kidney Int"},{"key":"10.1124\/dmd.120.000076_bib17","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1124\/dmd.113.052290","article-title":"Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17\u03b2-glucuronide, estrone-3-sulfate, and sulfobromophthalein","volume":"41","author":"Izumi","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000076_bib18","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1021\/acs.molpharmaceut.5b00664","article-title":"Investigation of fluorescein derivatives as substrates of organic anion transporting polypeptide (OATP) 1B1 to develop sensitive fluorescence-based OATP1B1 inhibition assays","volume":"13","author":"Izumi","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.120.000076_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cpt.1599","article-title":"Complex DDI by fenebrutinib and the use of transporter endogenous biomarkers to elucidate the mechanism of DDI","volume":"107","author":"Jones","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.000076_bib20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.4155\/bio-2017-0246","article-title":"UHPLC-MS\/MS bioanalysis of human plasma coproporphyrins as potential biomarkers for organic anion-transporting polypeptide-mediated drug interactions","volume":"10","author":"Kandoussi","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1124\/dmd.120.000076_bib21","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1124\/dmd.118.081794","article-title":"Simultaneous assessment of transporter-mediated drug-drug interactions using a probe drug cocktail in cynomolgus monkey","volume":"46","author":"Kosa","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000076_bib22","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40262-018-0648-3","article-title":"Clinical investigation of coproporphyrins as sensitive biomarkers to predict mild to strong OATP1B-mediated drug-drug interactions","volume":"57","author":"Kunze","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.120.000076_bib23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.116.234914","article-title":"Coproporphyrins in plasma and urine can Be appropriate clinical biomarkers to recapitulate drug-drug interactions mediated by organic anion transporting polypeptide inhibition","volume":"358","author":"Lai","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.120.000076_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejps.2010.03.009","article-title":"Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability","volume":"40","author":"Lappin","year":"2010","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.120.000076_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.addr.2017.07.020","article-title":"Evaluation of transporters in drug development: current status and contemporary issues","volume":"116","author":"Lee","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/dmd.120.000076_bib26","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/jcph.1261","article-title":"Effect of OATP1B1\/1B3 inhibitor GDC-0810 on the pharmacokinetics of pravastatin and coproporphyrin I\/III in healthy female subjects","volume":"58","author":"Liu","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.120.000076_bib27","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/0091270008319707","article-title":"Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine","volume":"48","author":"Liu","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.120.000076_bib28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejps.2014.04.004","article-title":"Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans","volume":"59","author":"Maeda","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.120.000076_bib29","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1124\/dmd.107.017814","article-title":"Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans","volume":"36","author":"Matsushima","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000076_bib30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1472-8206.2004.00254.x","article-title":"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans","volume":"18","author":"Molimard","year":"2004","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1124\/dmd.120.000076_bib31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/dmd.119.089474","article-title":"Alteration in the plasma concentrations of endogenous OATP1B-biomarkers in non-small cell lung cancer patients treated with paclitaxel","volume":"48","author":"Mori","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000076_bib32","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/pr.116.013326","article-title":"Biomarkers for in vivo assessment of transporter function","volume":"70","author":"M\u00fcller","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.120.000076_bib33","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1124\/dmd.119.087197","article-title":"Enhanced and persistent inhibition of organic cation transporter 1 activity by preincubation of cyclosporine A","volume":"47","author":"Panfen","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000076_bib34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/clpt.1981.208","article-title":"Kinetics and renal handling of cefonicid","volume":"30","author":"Pitkin","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.000076_bib35","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cpt.749","article-title":"Endogenous probes for drug transporters: balancing vision with reality","volume":"103","author":"Rodrigues","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.000076_bib36","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.4155\/bio-2018-0170","article-title":"LC-MS\/MS bioanalysis of plasma 1, 14-tetradecanedioic acid and 1, 16-hexadecanedioic acid as candidate biomarkers for organic anion-transporting polypeptide mediated drug-drug interactions","volume":"10","author":"Santockyte","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1124\/dmd.120.000076_bib37","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejphar.2006.04.047","article-title":"Tubular transporters and clearance of adefovir","volume":"540","author":"Servais","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.120.000076_bib38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.4155\/bio-2017-0265","article-title":"A pharmaceutical industry perspective on transporter and CYP-mediated drug-drug interactions: kidney transporter biomarkers","volume":"10","author":"Shen","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1124\/dmd.120.000076_bib39","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/dmd.117.075531","article-title":"Comparative evaluation of plasma bile acids, dehydroepiandrosterone sulfate, hexadecanedioate, and tetradecanedioate with coproporphyrins I and III as markers of OATP inhibition in healthy subjects","volume":"45","author":"Shen","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000076_bib40","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1124\/dmd.118.081125","article-title":"Further studies to support the use of coproporphyrin I and III as novel clinical biomarkers for evaluating the potential for organic anion transporting polypeptide 1B1 and OATP1B3 inhibition","volume":"46","author":"Shen","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000076_bib41","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/jpet.116.232066","article-title":"Coproporphyrins I and III as functional markers of OATP1B activity: in vitro and in vivo evaluation in preclinical species","volume":"357","author":"Shen","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.120.000076_bib42","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1124\/jpet.118.252643","article-title":"Evidence for the validity of pyridoxic acid (PDA) as a plasma-based endogenous probe for OAT1 and OAT3 function in healthy subjects","volume":"368","author":"Shen","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.120.000076_bib43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.semnephrol.2018.12.010","article-title":"Xenobiotic transporters in the kidney: function and role in toxicity","volume":"39","author":"Shen","year":"2019","journal-title":"Semin Nephrol"},{"key":"10.1124\/dmd.120.000076_bib44","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/jpet.112.200691","article-title":"Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation","volume":"344","author":"Shen","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.120.000076_bib45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11095-019-2593-8","article-title":"Recovery of OATP1B activity after living kidney transplantation in patients with end-stage renal disease","volume":"36","author":"Suzuki","year":"2019","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.120.000076_bib46","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11095-018-2416-3","article-title":"Comparative study of the dose-dependence of OATP1B inhibition by rifampicin using probe drugs and endogenous substrates in healthy volunteers","volume":"35","author":"Takehara","year":"2018","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.120.000076_bib47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/clpt.2013.77","article-title":"Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium","volume":"94","author":"Tweedie","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.000076_bib48","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1128\/AAC.17.5.847","article-title":"Effect of orally administered probenecid on the pharmacokinetics of cefoxitin","volume":"17","author":"Vlasses","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.120.000076_bib49","first-page":"692","article-title":"Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide","volume":"39","author":"Vree","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.120.000076_bib50","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2125.1979.tb01032.x","article-title":"Probenecid: an unexplained effect on cephalosporin pharmacology","volume":"8","author":"Welling","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.120.000076_bib51","doi-asserted-by":"crossref","unstructured":"Wiebe ST, Giessmann T, Hohl K, Schmidt-Gerets S, Hauel E, Jambrecina A, Bader K, Ishiguro N, Taub ME, Sharma A, et al. (2020) Validation of a drug transporter probe cocktail using the prototypical inhibitors rifampin, probenecid, verapamil, and cimetidine. Clin Pharmacokinet DOI: 10.1007\/s40262-020-00907-w [published ahead of print].","DOI":"10.1007\/s40262-020-00907-w"},{"key":"10.1124\/dmd.120.000076_bib52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0002-9343(76)90426-5","article-title":"Rotor\u2019s syndrome. A distinct inheritable pathophysiologic entity","volume":"60","author":"Wolkoff","year":"1976","journal-title":"Am J Med"},{"key":"10.1124\/dmd.120.000076_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clpt.2004.08.026","article-title":"Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics","volume":"77","author":"Yasui-Furukori","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.000076_bib54","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/cpt.434","article-title":"Metabolomic and genome-wide association studies reveal potential endogenous biomarkers for OATP1B1","volume":"100","author":"Yee","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.000076_bib55","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/cts.12625","article-title":"Organic anion transporter polypeptide 1B1 polymorphism modulates the extent of drug-drug interaction and associated biomarker levels in healthy volunteers","volume":"12","author":"Yee","year":"2019","journal-title":"Clin Transl Sci"},{"key":"10.1124\/dmd.120.000076_bib56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1124\/dmd.118.084905","article-title":"Mechanisms and clinical significance of pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration in 2017","volume":"47","author":"Yu","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000076_bib57","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1021\/acs.molpharmaceut.8b01226","article-title":"Dissecting the contribution of OATP1B1 to hepatic uptake of statins using the OATP1B1 selective inhibitor estropipate","volume":"16","author":"Zhang","year":"2019","journal-title":"Mol Pharm"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.120.000076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:52:31Z","timestamp":1740055951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624080358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0090955624080358"],"URL":"https:\/\/doi.org\/10.1124\/dmd.120.000076","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of Weak Organic Anion\u2013Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.120.000076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}